Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone

被引:0
作者
Masanobu Kanou
Toru Usui
Hisao Ueyama
Hiroshi Sato
Iwao Ohkubo
Takaharu Mizutani
机构
[1] Nagoya City University,Graduate School of Pharmaceutical Sciences
[2] Shiga University of Medical Science,undefined
来源
Molecular Biology Reports | 2004年 / 31卷
关键词
dexamethasone; UDP-glucuronosyltransferase; phenobarbital; glucocorticoid;
D O I
暂无
中图分类号
学科分类号
摘要
Human UDP-glucuronosyltransferase (UGT) 1A1 is only enzyme in the conjugation of bilirubin for prevention of hyperbilirubinemia and jaundice. Deletion or mutation of the UGT1A1 gene causes Crigler-Najjar syndrome or Gilbert's syndrome. We previously reported the functional promoter region for expression of UGT1A1 [Hepatology Research 9, 152–163 (1997)]. We investigated the influence of some drugs on the transient transfection assay of the luciferase reporter gene containing the 5′-promoter region −3174/+14 of UGT1A1 in HepG2 cells. Among drugs investigated, dexamethasone was the most effective at the range of concentration of 10–100 μM, whereas stimulation by β-estradiol was not found. We also could not find stimulation by bilirubin of the endogenous main substrate for UGT1A1. Stimulation by dexamethasone was continued for 48 hr. The luciferase reporter gene containing the 5′-region of −97/+14 was induced by dexamethasone but the gene of the 5′-region −53/+14 was not. The region −97/−53 is essential for induction by dexamethasone. This region contains HNF1 element, therefore, we speculated that dexamethasone directly and/or indirectly stimulates UGT1A1 expression through this HNF1 region in the promoter region of UGT1A1. Thus, we clarified that UGT1A1 was induced by dexamethasone and the key position was the region (−97/−53) in UGT1A1 promoter.
引用
收藏
页码:151 / 158
页数:7
相关论文
共 142 条
  • [1] Evans WE(1999)An active metabolite of morphine and the re-sponsible glucuronosyltransferase for its formation Science 286 487-491
  • [2] Relling MV(2000)undefined Drug Metab. Dispos. 28 661-663
  • [3] King C(1999)undefined Drug Metab. Rev. 31 817-899
  • [4] Finley B(2001)undefined Drug Met. Rev. 33 273-297
  • [5] Franklin R(1988)undefined Arch. Biochem. Biophys. 263 216-225
  • [6] Radominska-Pandoya A(1992)undefined J. Biochem. 112 192-196
  • [7] Czernik PJ(1977)undefined Biochem. J. 164 737-746
  • [8] Little JM(2000)undefined Ann. Rev. Pharmacol. Toxicol. 40 581-616
  • [9] Battaglia E(2001)undefined Mol. Pharmcol. 59 405-414
  • [10] Mackenzie PI(1984)undefined J. Biol. Chem. 259 11791-11705